Citrulline Allo. Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children

• Conditions: Benign Disease

• Registration Number: NCT00751452
• Lead Sponsor: University Hospital, Clermont-Ferrand

Brief Summary

determine the interest of the dosage of citrullinemia to monitor the bowel damage after allogeneic bone marrow transplantation in children.

Detailed Description

30 children included. Dosage of citrullinemia on day -7, day 0 and every week up to 100 days after BMT. Histological examination and extensive infectious screening in case of persistent digestive symptoms (more than 3 days).

Two groups of patients regarding on digestive involvement. Comparison of the values of citrullinemia between these two groups.

Study Timeline

• Study Start: 2008-04
• Study First Submitted: 2008-09-09
• Study First Submitted QC: 2008-09-11
• Study First Posted: 2008-09-12
• Primary Completion: 2009-09
• Study Completion: 2009-09
• Status Verified: 2011-01
• Last Update Submitted: 2011-01-18
• Last Update Posted: 2011-01-19

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• 0 to 18 years
• allogeneic bone marrow transplantation for malignant or benign disease
• affiliation to French sécurité sociale
• parent's consent

Exclusion Criteria

• severe gastro-intestinal involvement before transplant
• previous digestive surgery

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Citrullinemia (weekly)	weekly

Secondary Outcome Measures

Name	Time	Method
Gastro-intestinal complications in children following allogeneic bone marrow transplantation	following allogenic bone marrow transplantation

Trial Locations

Locations (1)

Etienne MERLIN; 🇫🇷 Clermont-Ferrand, France